CULLINAN THERAPEUTICS, INC. Subsidiary or Equity Method Investee, Cumulative Proceeds Received on All Transactions
CULLINAN THERAPEUTICS, INC. (CGEM) reported Subsidiary or Equity Method Investee, Cumulative Proceeds Received on All Transactions of $277.90 million for the 12-month period ending 2023-12-31, per its 10-K filed 2024-03-14.
Discontinued › Notes › Equity
us-gaap:SubsidiaryOrEquityMethodInvesteeCumulativeProceedsReceivedOnAllTransactions · last filed 2024-03-14
- CULLINAN THERAPEUTICS, INC. subsidiary or equity method investee, cumulative proceeds received on all transactions for the quarter ending 2023-12-31 was $0.00.
- CULLINAN THERAPEUTICS, INC. subsidiary or equity method investee, cumulative proceeds received on all transactions for the quarter ending 2023-09-30 was $0.00.
- CULLINAN THERAPEUTICS, INC. subsidiary or equity method investee, cumulative proceeds received on all transactions for the quarter ending 2022-12-31 was $0.00.
- CULLINAN THERAPEUTICS, INC. subsidiary or equity method investee, cumulative proceeds received on all transactions for the quarter ending 2022-09-30 was $0.00.
- CULLINAN THERAPEUTICS, INC. subsidiary or equity method investee, cumulative proceeds received on all transactions for fiscal 2023 was $277.90M, a 0.00% change from fiscal 2022.
- CULLINAN THERAPEUTICS, INC. subsidiary or equity method investee, cumulative proceeds received on all transactions for fiscal 2022 was $277.90M.
| Period end | Subsidiary or Equity Method Investee, Cumulative Proceeds Received on All Transactions 3 month | Subsidiary or Equity Method Investee, Cumulative Proceeds Received on All Transactions 6 month | Subsidiary or Equity Method Investee, Cumulative Proceeds Received on All Transactions 9 month | Subsidiary or Equity Method Investee, Cumulative Proceeds Received on All Transactions 12 month |
|---|---|---|---|---|
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $0.00 derived: sum of 2 quarters · filed 2024-03-14 | $277.90M 10-K · filed 2024-03-14 | |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $277.90M 10-Q · filed 2023-11-08 | ||
| 2023-06-30 | $277.90M 10-Q · filed 2023-08-10 | |||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | $0.00 derived: sum of 2 quarters · filed 2023-03-09 | $277.90M 10-K · filed 2023-03-09 | |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $277.90M 10-Q · filed 2022-11-14 | ||
| 2022-06-30 | $277.90M 10-Q · filed 2022-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |